Vai direttamente al contenuto

Anemia drepanocitica (età pediatrica)

Gestione dell’anemia

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (apre una nuova finestra)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Fonte‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indicizzato‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (apre una nuova finestra)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (apre una nuova finestra)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Fonte‎: Acta Haematol 1995;94(3):128-34.

Indicizzato‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (apre una nuova finestra)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (apre una nuova finestra)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Fonte‎: Haematologica 2006;91(8):1076-83.

Indicizzato‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (apre una nuova finestra)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (apre una nuova finestra)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Fonte‎: J Obstet Gynaecol 2007;27(1):82-3.

Indicizzato‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (apre una nuova finestra)